TNGX Q3 2025 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M+363.6% YoY

Gross Profit

$53M99.0% margin

Operating Income

$14M26.2% margin

Net Income

$16M29.5% margin

EPS (Diluted)

$0.14

QoQ Revenue Growth

+1591.6%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$210M

Total Liabilities

$50M

Stockholders' Equity

$160M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$12M	+363.6%
Gross Profit	$53M	$12M	+358.8%
Operating Income	$14M	-$33M	+142.8%
Net Income	$16M	-$29M	+154.5%

Revenue Segments

Collaboration Revenue

$54M100%